Insider · CIK 0001542519
Jerrold B Grossman
Files at ADMA (ADMA BIOLOGICS, INC.). First filing Jun 10, 2025, latest May 28, 2026.
In brief
Jerrold B Grossman files SEC Form 4 as director at ADMA (ADMA BIOLOGICS, INC.). Since Jun 10, 2025, Jerrold B Grossman has reported 3 open-market buys worth $251k and 1 open-market sell worth $213k, the latest filed on May 28, 2026.
A track record needs three past buys with six months of prices behind them; Jerrold B Grossman has 0, so none is measured yet.
The newest scored trade: bought $51k of ADMA on May 27, 2026, filed May 28, 2026, scored 45 (moderate). In the last 12 months: 3 buys worth $251k and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ADMA: ADMA BIOLOGICS, INC.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 45Moderate | ADMAbuy ADMA BIOLOGICS, INC. | $51k 6,400 shares | +1% | +1% from low-64% from high | |
| 48Moderate | ADMAbuy ADMA BIOLOGICS, INC. | $100k 12,500 shares | +2% | +7% from low-62% from high | |
| 43Moderate | ADMAbuy ADMA BIOLOGICS, INC. | $100k 12,500 shares | +3% | 0% from low-64% from high | |
| 27Weak | ADMA BIOLOGICS, INC. | $213k 10,000 shares | -2% | +35% from low-15% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jun 9, 2025 | ADMA ADMA BIOLOGICS, INC. | 10,000 0.00% of outstanding | $206k | Jun 9, 2025 | none |
Transactions
Every row this insider has filed, 10 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 27, 2026 | ADMA ADMA BIOLOGICS, INC. | POpen-market purchase Common Stock | +6,400 | $7.91 | $51k | 520,284 | May 28, 2026 |
| May 12, 2026 | ADMA ADMA BIOLOGICS, INC. | POpen-market purchase Common Stock | +12,500 | $8.01 | $100k | 513,884 | May 14, 2026 |
| May 11, 2026 | ADMA ADMA BIOLOGICS, INC. | POpen-market purchase Common Stock | +12,500 | $8.01 | $100k | 501,384 | May 12, 2026 |
| Feb 9, 2026 | ADMA ADMA BIOLOGICS, INC. | AGrant or award Common Stock | +10,690 | $0.00 | $0 | 488,884 | Feb 11, 2026 |
| Feb 9, 2026 | ADMA ADMA BIOLOGICS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +17,730 | $0.00 | $0 | 17,730 | Feb 11, 2026 |
| Jun 9, 2025 | ADMA ADMA BIOLOGICS, INC. | MOption exercise Common Stock | +10,000 | $5.00 | $50k | 488,194 | Jun 10, 2025 |
| Jun 9, 2025 | ADMA ADMA BIOLOGICS, INC. | SOpen-market sale Common Stock | -10,000 | $21.31 | $213k | 478,194 | Jun 10, 2025 |
| Jun 9, 2025 | ADMA ADMA BIOLOGICS, INC. | MOption exercise Stock Option (right to buy)derivative | -10,000 | $0.00 | $0 | 0 | Jun 10, 2025 |
| Feb 19, 2025 | ADMA ADMA BIOLOGICS, INC. | AGrant or award Common Stock | +10,889 | $0.00 | $0 | 478,194 | Feb 21, 2025 |
| Feb 19, 2025 | ADMA ADMA BIOLOGICS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +16,279 | $0.00 | $0 | 16,279 | Feb 21, 2025 |
Questions about Jerrold B Grossman
Answered from the filings on this page, as of the latest one.
Is Jerrold B Grossman buying or selling?
In the last 12 months Jerrold B Grossman reported 3 open-market buys worth $251k and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $51k of ADMA on May 27, 2026. Grants, option exercises and tax withholding are not counted.
How did Jerrold B Grossman's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Jerrold B Grossman has 0.
Where does Jerrold B Grossman file Form 4?
Jerrold B Grossman has filed Form 4 at ADMA (ADMA BIOLOGICS, INC.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.